TY  - JOUR
AB  - Drug resistance to a single agent is common in cancer-targeted therapies, and rational drug combinations are a promising approach to overcome this challenge. Many Food and Drug Administration-approved drugs can induce cellular senescence, which possesses unique vulnerabilities and molecular signatures. However, there is limited analysis on the effect of the combination of cellular-senescence-inducing drugs and targeted therapy drugs. Here, we conducted a comprehensive evaluation of cellular senescence using 7 senescence-associated gene sets. We quantified the cellular senescence states of ~10,000 tumor samples from The Cancer Genome Atlas and examined their associations with targeted drug responses. Our analysis revealed that tumors with higher cellular senescence scores exhibited increased sensitivity to targeted drugs. As a proof of concept, we experimentally confirmed that etoposide-induced senescence sensitized lung cancer cells to 2 widely used targeted drugs, erlotinib and dasatinib. Furthermore, we identified multiple genes whose dependencies were associated with senescence status across ~1,000 cancer cell lines, suggesting that cellular senescence generates unique vulnerabilities for therapeutic exploitation. Our study provides a comprehensive overview of drug response related to cellular senescence and highlights the potential of combining senescence-inducing agents with targeted therapies to improve treatment outcomes in lung cancer, revealing novel applications of cellular senescence in targeted cancer therapies.
AU  - Zhou, X.*
AU  - Zhu, X.*
AU  - Wang, W.
AU  - Wang, J.*
AU  - Wen, H.*
AU  - Zhao, Y.*
AU  - Zhang, J.*
AU  - Xu, Q.*
AU  - Zhao, Z.*
AU  - Ni, T.*
C1  - 73090
C2  - 56908
CY  - 1200 New York Ave, Nw, Washington, Dc 20005 Usa
TI  - Comprehensive cellular senescence evaluation to aid targeted therapies.
JO  - Research
VL  - 8
PB  - Amer Assoc Advancement Science
PY  - 2025
SN  - 2639-5274
ER  - 

TY  - JOUR
AB  - The increasingly aging society led to a rise in the prevalence of chronic wounds (CWs), posing a significant burden to public health on a global scale. One of the key features of CWs is the presence of a maladjusted immune microenvironment characterized by persistent and excessive (hyper)inflammation. A variety of immunomodulatory therapies have been proposed to address this condition. Yet, to date, current delivery systems for immunomodulatory therapy remain inadequate and lack efficiency. This highlights the need for new therapeutic delivery systems, such as nanosystems, to manage the pathological inflammatory imbalance and, ultimately, improve the treatment outcomes of CWs. While a plethora of immunomodulatory nanosystems modifying the immune microenvironment of CWs have shown promising therapeutic effects, the literature on the intersection of immunomodulatory nanosystems and CWs remains relatively scarce. Therefore, this review aims to provide a comprehensive overview of the pathogenesis and characteristics of the immune microenvironment in CWs, discuss important advancements in our understanding of CW healing, and delineate the versatility and applicability of immunomodulatory nanosystems-based therapies in the therapeutic management of CWs. In addition, we herein also shed light on the main challenges and future perspectives in this rapidly evolving research field.
AU  - Chu, X.*
AU  - Xiong, Y.*
AU  - Knoedler, S.
AU  - Lu, L.*
AU  - Panayi, A.C.*
AU  - Alfertshofer, M.*
AU  - Jiang, D.
AU  - Rinkevich, Y.
AU  - Lin, Z.*
AU  - Zhao, Z.*
AU  - Guandong, L.*
AU  - Bobin, M.*
AU  - Guohui, L.*
C1  - 68372
C2  - 53642
CY  - 1200 New York Ave, Nw, Washington, Dc 20005 Usa
TI  - Immunomodulatory nanosystems: Advanced delivery tools for treating chronic wounds.
JO  - Research
VL  - 6
PB  - Amer Assoc Advancement Science
PY  - 2023
SN  - 2639-5274
ER  -